Professor Carling is investigating two proteins involved in prostate cancer growth to determine whether they can be used as targets for a dual drug treatment for advanced prostate cancer.
Dr Halldén hopes to build on her previous work on a virus that specifically kills cancer cells, which can be used in combination with chemotherapy to treat advanced prostate cancer.
Dr Tait will test if a new treatment that activates men’s immune systems can be used to kill cancer cells in advanced prostate cancer, and prevent resistance to treatment.
Professor Ahmed and Mr Taimur Shah want to test focal therapy against standard treatments, so that it can be made available to men and improve their quality of life after prostate cancer.
Professor Bevan and Dr Fletcher will investigate the role of newly discovered molecules in advanced prostate cancer becoming treatment resistant, with the goal of developing new drugs.
We’re funding Dr Swain to create mini prostate cancer tumours in the lab to look for genes that allow tumours to grow, respond to treatment and become resistant to treatment. The project could go on to inform precision medicine trials for advanced prostate cancer treatments.
Professor de Bono will investigate why drugs like abiraterone and enzalutamide don’t work for some men, and why they stop working for others. A better understanding of this process will help scientists develop drugs to prevent resistance to these treatments and extend the lives of men with advanced prostate cancer.
Professor Mendes aims to develop a new test, that can be used alongside the PSA test, to accurately determine which men have aggressive prostate cancer and need immediate therapy, and which men can be spared unnecessary treatments.
Centres of excellence bring researchers together to tackle big questions and move research towards practice.
The researchers have already designed and validated key components of a vaccine to treat and prevent prostate cancer. In this project, they will put all the parts together and test them to make the vaccine as effective as possible.
Dr Wang’s team will use mouse models to investigate whether exercise inhibits prostate cancer cells’ ability to move into, and grow in, bones.
Dr Tree is conducting a clinical trial of men whose cancer has begun to grow after treatment with abiraterone or enzalutamide. She wants to see whether hitting the growing metastatic lesions with precisely targeted radiotherapy can prolong the time that the rest of the cancer responds to hormone therapy.
Dr Munkley will investigate why the loss of sugar groups on the outside of the cell leads to prostate cancer cell death, and whether she can use existing anti-glycosylation drugs to exploit this as a potential new treatment for aggressive prostate cancer.
Dr Tierney and her colleagues will review data from clinical trials worldwide in new and different ways. This will help them to work out which are the best current treatments for advanced prostate cancer as quickly as possible, and identify clinical measurements that predict treatment success to try to speed up future trials.
This team of PhD and clinical scientists aims to postpone surgery by reprogramming immune cells in the prostate to prevent cancers growing back after primary treatment.
Dr Armstrong aims to develop new drugs to use alongside radiotherapy for prostate cancer and reduce the risk of recurrence after treatment.
Dr Susan Heavey plans to use a new method of culturing prostate cancer samples in the lab to test new drug combinations, and use cutting edge technologies to predict and monitor response to treatment.
Our first Travelling Prize Fellow will be working with a team in Rotterdam to develop the skills to develop drugs for treating prostate cancer.
We are funding Professor de Bono and his team to develop a simple genetic test to work out which men have this mutation. This will help them to give a more accurate prognosis to men with this mutation and to recruit them for a bigger clinical trial of olaparib.
Dr Crispin Miller will train a PhD student to develop computer models to predict how men with advanced prostate cancer will respond to treatment. Ultimately this work will help us to get better at matching the treatment given to an individual man’s cancer.
Dr Hector Keun and his PhD student will unlock the power of microRNAs to distinguish aggressive cancers from low-risk ones and to tell us which is likely to be the best treatment for an individual man’s cancer.
Professor Johann de Bono and his PhD student will gather and analyse the masses of genetic data available from prostate cancer patients’ biopsy and blood samples to work out which treatments, and which clinical trials, might work best for them.
We’ve granted £83,979 to Dr Daniel Brewer at the University of East Anglia to train a PhD student to analyse data that might allow us to make sense of the mysterious prostate cancer field effect. This could have major implications for which treatments men should choose and also, one day, for preventing the disease.
Dr Sharp aims to identify proteins that bind to altered versions of the androgen receptor, and investigate whether blocking their activity can hinder cancer progression.
Dr Feber and his team aim to improve the way that prostate cancer is diagnosed and monitored. They’ve developed a test that looks at prostate cancer specific DNA modifications that can be detected in the blood of men with prostate cancer.